Kite Pharma Company Profile (NASDAQ:KITE)

About Kite Pharma

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KITE
  • CUSIP:
Key Metrics:
  • Previous Close: $53.68
  • 50 Day Moving Average: $50.78
  • 200 Day Moving Average: $52.09
  • 52-Week Range: $39.82 - $64.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.12
  • P/E Growth: 0.00
  • Market Cap: $2.68B
  • Outstanding Shares: 49,875,000
  • Beta: 2.63
  • Net Margins: -994.89%
  • Return on Equity: -39.26%
  • Return on Assets: -33.81%
  • Current Ratio: 10.37%
  • Quick Ratio: 10.37%
Additional Links:
Companies Related to Kite Pharma:

Analyst Ratings

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (?)
Ratings Breakdown: 4 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $70.07 (30.54% upside)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
DateFirmActionRatingPrice TargetDetails
2/22/2017HC WainwrightReiterated RatingBuy$78.00View Rating Details
2/22/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformView Rating Details
2/1/2017WedbushInitiated CoverageNeutral$46.00View Rating Details
1/24/2017Jefferies Group LLCReiterated RatingBuy$72.00View Rating Details
1/17/2017Maxim GroupReiterated RatingBuy$77.00View Rating Details
1/8/2017FBR & CoSet Price TargetBuy$78.00View Rating Details
1/4/2017Roth CapitalInitiated CoverageBuy$68.00View Rating Details
12/12/2016Stifel NicolausReiterated RatingBuyView Rating Details
11/29/2016Canaccord GenuitySet Price TargetBuy$75.00View Rating Details
11/24/2016RBC Capital MarketsReiterated RatingBuyView Rating Details
11/22/2016BTIG ResearchReiterated RatingHoldView Rating Details
10/19/2016Cowen and CompanyReiterated RatingBuyView Rating Details
10/10/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$70.00View Rating Details
9/27/2016Barclays PLCBoost Price TargetEqual Weight$60.00 -> $65.00View Rating Details
8/9/2016MizuhoSet Price TargetBuy$80.00View Rating Details
6/2/2016Raymond James Financial, Inc.Initiated CoverageOutperform$61.00View Rating Details
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
3/20/2016SunTrust Banks, Inc.Reiterated RatingBuy$70.00View Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$67.00View Rating Details
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details
8/14/2015GuggenheimReiterated RatingBuyView Rating Details
5/5/2015Credit Suisse GroupReiterated RatingOutperform$79.00View Rating Details
(Data available from 2/22/2015 forward)


Earnings History for Kite Pharma (NASDAQ:KITE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016Q316($1.63)($1.49)$4.94 million$7.34 millionViewListenView Earnings Details
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.60)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.54)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.38)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.40)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$0.12($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.20)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Kite Pharma (NASDAQ:KITE)
Current Year EPS Consensus Estimate: $-5.53 EPS
Next Year EPS Consensus Estimate: $-6.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.37)($0.93)($1.09)
Q2 20163($1.30)($1.15)($1.24)
Q3 20163($1.74)($1.66)($1.70)
Q4 20165($2.01)($1.52)($1.76)
Q1 20173($1.70)$0.08($1.09)
Q2 20173($1.79)($1.70)($1.76)
Q3 20173($1.83)($0.95)($1.49)
Q4 20173($1.48)($1.40)($1.44)
(Data provided by Zacks Investment Research)


Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Kite Pharma (NASDAQ:KITE)
Insider Ownership Percentage: 20.60%
Institutional Ownership Percentage: 80.73%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2017Cynthia M ButittaCOOSell10,000$50.56$505,600.00View SEC Filing  
1/6/2017Cynthia M ButittaCOOSell10,000$50.13$501,300.00View SEC Filing  
1/6/2017Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
12/20/2016Arie BelldegrunChairmanSell3,493$50.86$177,653.98View SEC Filing  
12/20/2016Cynthia M ButittaCOOSell2,482$50.86$126,234.52View SEC Filing  
12/20/2016David D. ChangEVPSell1,788$50.86$90,937.68View SEC Filing  
12/20/2016Jeffrey WiezorekSVPSell716$50.86$36,415.76View SEC Filing  
12/20/2016Shawn TomaselloInsiderSell4,901$50.86$249,264.86View SEC Filing  
12/1/2016Jeffrey WiezorekSVPSell1,500$50.76$76,140.00View SEC Filing  
11/25/2016Cynthia M ButittaCOOSell10,000$50.40$504,000.00View SEC Filing  
10/3/2016Jeffrey WiezorekSVPSell1,500$54.81$82,215.00View SEC Filing  
9/26/2016Cynthia M ButittaCOOSell10,000$54.13$541,300.00View SEC Filing  
9/1/2016Jeffrey WiezorekSVPSell1,500$58.24$87,360.00View SEC Filing  
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.00View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.00View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Kite Pharma (NASDAQ:KITE)
News IconKite Pharma Inc (KITE) is Initiated by Wells Fargo to “Market Perform ... - Highland Mirror (NASDAQ:KITE) - February 22 at 6:20 PM logoNoteworthy Tuesday Option Activity: AAP, KITE, HCI (NASDAQ:KITE) - February 22 at 12:24 PM logoAnalyst Activity – Wells Fargo & Company Initiates Coverage On Kite Pharma (NASDAQ:KITE) With a Outperform (NASDAQ:KITE) - February 22 at 12:24 PM
News Icon“Liver Cancer – Pipeline Review, H2 2016” Now Available at Fast Market Research (NASDAQ:KITE) - February 20 at 10:26 AM
News IconKite Pharma Inc KITE Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:KITE) - February 18 at 5:29 PM
News IconSell-side is Weighing in on Kite Pharma, Inc. (NASDAQ:KITE) Earnings & Targets - Aiken Advocate (NASDAQ:KITE) - February 18 at 12:07 PM
News IconKite Pharma, Inc. (NASDAQ:KITE) Daily Sentiment Score At 0.207 - Stock Observer (NASDAQ:KITE) - February 15 at 5:40 AM logoForm SC 13G/A Kite Pharma, Inc. Filed by: FMR LLC - (NASDAQ:KITE) - February 15 at 5:40 AM logoForm SC 13G/A Kite Pharma, Inc. Filed by: FMR LLC (NASDAQ:KITE) - February 14 at 7:36 PM
News IconNotable Monday Option Activity: WTW, KITE, OA (NASDAQ:KITE) - February 13 at 7:12 PM
News IconWhy Kite Pharma, Inc. Stock Rose 13% in January - Fox Business (NASDAQ:KITE) - February 7 at 4:21 AM logoWhy Kite Pharma, Inc. Stock Rose 13% in January (NASDAQ:KITE) - February 6 at 6:16 PM
News IconQuarterly EPS Of Kite Pharma, Inc. (NASDAQ:KITE) Set At $-1.12 - Stock Observer (NASDAQ:KITE) - February 5 at 10:53 PM logoCoverage initiated on Kite Pharma by Wedbush (NASDAQ:KITE) - February 2 at 6:51 PM logoKITE Crosses Above Key Moving Average Level (NASDAQ:KITE) - February 1 at 6:59 PM logoKite Pharma, Inc. breached its 50 day moving average in a Bullish Manner : KITE-US : February 1, 2017 (NASDAQ:KITE) - February 1 at 6:59 PM
News IconTrading Circle: Narrowing in on Shares of Kite Pharma, Inc. (NASDAQ:KITE) - The Tribune (NASDAQ:KITE) - January 29 at 11:30 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Kite Pharma ... - Aiken Advocate (NASDAQ:KITE) - January 29 at 11:30 PM
News IconUpdate on Valuation Formula's For Kite Pharma, Inc. (NASDAQ:KITE) - The Tribune (NASDAQ:KITE) - January 29 at 4:22 AM
News IconChart Inspection on Shares of Kite Pharma Inc. (KITE) - Springdale Times (NASDAQ:KITE) - January 27 at 8:16 PM logoBRIEF-Teva pharmaceutical industries' Arie Belldegrun resigned as a member of the board (NASDAQ:KITE) - January 27 at 12:55 AM
News IconEarnings in Full Force, Analysts Take Aim at Kite Pharma, Inc. (NASDAQ:KITE) - Wall Street Beacon (NASDAQ:KITE) - January 26 at 7:54 PM
News IconKite Pharma, Inc. (NASDAQ:KITE) Bearish Target At $80 - Stock Observer (NASDAQ:KITE) - January 26 at 5:36 AM
News IconMarkus Spielmann Inc. Initiates Coverage on Kite Pharma on Potential of KTE-C19 (NASDAQ:KITE) - January 25 at 7:35 PM
News IconAs Kite Pharma INC (KITE) Stock Rose, Shareholder Bainco International Investors Boosted Stake by $35.63 Million (NASDAQ:KITE) - January 25 at 7:35 PM logoInteresting KITE Put And Call Options For March 17th (NASDAQ:KITE) - January 25 at 5:03 AM
News IconBiotech Stocks Under Scanner -- Kite Pharma, BioPharmX, OvaScience, and Regeneron Pharma (NASDAQ:KITE) - January 23 at 10:37 AM logoBank of New York Mellon : The Kite Pharma, Inc. (Kite) Position Lowered by Bank of New York Mellon Corp (NASDAQ:KITE) - January 20 at 4:23 PM logoKite Pharma : and Fosun Pharma Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer (NASDAQ:KITE) - January 19 at 7:56 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Kite Pharma, Inc. (NASDAQ:KITE) - Wall Street Beacon (NASDAQ:KITE) - January 18 at 11:43 PM logoKite Pharma, Inc. breached its 50 day moving average in a Bearish Manner : KITE-US : January 18, 2017 (NASDAQ:KITE) - January 18 at 6:42 PM
News IconReady for an Upsurge? Analysts Chime in on Kite Pharma, Inc. (NASDAQ:KITE) - Prospect Journal (NASDAQ:KITE) - January 17 at 12:26 PM logoBiogen (BIIB) Presents Positive Phase III Data on Spinraza (NASDAQ:KITE) - January 16 at 8:35 AM logoKite Outlines CAR-T Cancer Drug Marketing Plan (KITE) (NASDAQ:KITE) - January 13 at 7:24 PM logoKite Pharma Details CAR-T Cancer Drug Marketing (NASDAQ:KITE) - January 13 at 7:24 PM logoNovartis to Conduct Trial on Obese, Type II Diabetes Patients (NASDAQ:KITE) - January 13 at 7:24 PM logoKeryx Releases Auryxia Data for Iron Deficiency Anemia (NASDAQ:KITE) - January 13 at 7:24 PM
News IconMonitoring Relative Strength Index Values for Kite Pharma Inc. (KITE) - Wall Street Beacon (NASDAQ:KITE) - January 12 at 11:42 PM
News IconWill The Needle Move For Kite Pharma, Inc. (NASDAQ:KITE) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:KITE) - January 12 at 11:42 PM logoKite Pharma CEO Belldegrun on Cancer Drugs, Prices (NASDAQ:KITE) - January 12 at 6:41 PM
News IconKite Pharma, Inc. (NASDAQ:KITE) Bearish Target At $80 | Stock ... - Stock Observer (NASDAQ:KITE) - January 12 at 4:49 AM logoKite Gets Chinese Partner for CAR-T Therapy (KITE) (NASDAQ:KITE) - January 11 at 6:46 PM logoPuts showing caution in Kite Pharma (NASDAQ:KITE) - January 11 at 6:46 PM logoKite Pharma In Cancer Drug Pact With China's Fosun (NASDAQ:KITE) - January 11 at 6:46 PM logoWhat's behind put in Kite Pharma (NASDAQ:KITE) - January 11 at 5:06 AM
News IconKite Pharma, Inc. (NASDAQ:KITE) Daily Sentiment Score At 0.337 - Stock Observer (NASDAQ:KITE) - January 11 at 12:02 AM logoBRIEF-Kite Pharma and Fosun Pharma establish joint venture in China - Reuters (NASDAQ:KITE) - January 11 at 12:02 AM logoKite Pharma partners with Japan's Daiichi for cancer therapy - Reuters (NASDAQ:KITE) - January 11 at 12:02 AM logoKite Pharma, Inc. (NASDAQ:KITE) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:KITE) - January 10 at 7:01 PM logoKite, Fosun Pharma form JV in China for cancer treatment (NASDAQ:KITE) - January 10 at 7:01 PM


What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

Where is Kite Pharma's stock going? Where will Kite Pharma's stock price be in 2017?

19 brokerages have issued 1-year target prices for Kite Pharma's shares. Their predictions range from $46.00 to $80.00. On average, they expect Kite Pharma's stock price to reach $70.07 in the next year.

When will Kite Pharma announce their earnings?

Kite Pharma is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Kite Pharma stock?

Here are some recent quotes from research analysts about Kite Pharma stock:

  • According to Zacks Investment Research, "Kite Pharma is focused on the development of immuno-oncology treatments and is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer. Kite Pharma continues to progress with its pipeline and initiated a rolling submission of the BLA for KTE-C19, its lead pipeline candidate, for a broader label for aggressive NHL in Dec 2016. KTE-C19 looks well poised for launch in 2017. Moreover, a number of key data readouts are expected in 2017. Loss estimates have remained stable ahead of the company’s Q4 results. The company has a mixed record of earnings surprises in recent quarters. However, with no approved product yet in its portfolio, any setback in the development/regulatory process for KTE-C19 would weigh heavily on the stock. Moreover, there are several other companies working to bring innovative immuno-oncology treatments to market." (2/8/2017)

  • Wedbush analysts commented, "KITE is poised to complete submission of the first BLA for a CAR-T therapy, but we believe slow adoption of the new treatment modality may blunt its first mover advantage, as CAR-T competition matures and treatment strategies evolve to address safety and efficacy challenges." (2/1/2017)
  • Jefferies Group LLC analysts commented, "Recently, a debate has arisen over pot’l Zuma-1 efficacy differences across autologous stem cell transplant (ASCT)-relapsed and refractory pts due to semantics around the word relapsed". We believe little distinction has been given to the ASCT-relapsed group within the larger relapsed population with the perception that ASCT-relapsed pts are healthier than refractory pts." (11/23/2016)

  • Canaccord Genuity analysts commented, "BeiGene presented updated clinical data for its BTK inhibitor BGB-3111 in patients with Waldenström’s Macroglobulinemia (WM) at the International Workshop on Waldenström’s Macroglobulinemia and Symposium on Advances in Multiple Myeloma (IWWM-9) in Amsterdam, the Netherlands." (10/7/2016)

  • Barclays PLC analysts commented, "While we need to wait for clarity on durability, (doctors would like to see a med of ~9+ months), based on the Ph1 ZUMA patients, CRs at 3 months appear to be durable out to 9 months, which is encouraging. It will also be important to see CR rates in both chemo-refractory vs. relapse after stem cell transplant (SCT) (the prior being the higher hurdle), however in our view any differences, unless profound, would be unlikely to prevent approval in both patient settings," (9/27/2016)

Who owns Kite Pharma stock?

Kite Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.94%), Menora Mivtachim Holdings LTD. (2.52%), FMR LLC (1.81%), Frontier Capital Management Co. LLC (0.94%), Capital Guardian Trust Co. (0.93%) and First Republic Investment Management Inc. (0.78%). Company insiders that own Kite Pharma stock include Arie Belldegrun, Cynthia M Butitta, David D Chang, Helen Susan Kim, Jeffrey Wiezorek, Marc Better, Margo R Roberts, Ran Nussbaum, Rizwana F Sproule, Roy Doumani and Shawn Tomasello.

Who sold Kite Pharma stock? Who is selling Kite Pharma stock?

Kite Pharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Eventide Asset Management LLC, Raymond James Financial Services Advisors Inc., Allianz Asset Management AG, Capital Guardian Trust Co., Guggenheim Capital LLC and Asset Management One Co. Ltd.. Company insiders that have sold Kite Pharma stock in the last year include Arie Belldegrun, Cynthia M Butitta, David D Chang, Helen Susan Kim, Jeffrey Wiezorek, Margo R Roberts, Rizwana F Sproule, Roy Doumani and Shawn Tomasello.

Who bought Kite Pharma stock? Who is buying Kite Pharma stock?

Kite Pharma's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Deerfield Management Co., Menora Mivtachim Holdings LTD., Frontier Capital Management Co. LLC, Pinnacle Associates Ltd., ARK Investment Management LLC, First Republic Investment Management Inc. and Russell Investments Group Ltd..

How do I buy Kite Pharma stock?

Shares of Kite Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kite Pharma stock cost?

One share of Kite Pharma stock can currently be purchased for approximately $53.68.

Kite Pharma (NASDAQ:KITE) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Earnings History Chart

Earnings by Quarter for Kite Pharma (NASDAQ:KITE)

Dividend History Chart

Dividend Payments by Quarter for Kite Pharma (NASDAQ:KITE)

Last Updated on 2/22/2017 by Staff